Sivenius J, Ylinen A, Murros K, Mumford J P, Riekkinen P J
Department of Neurology, University of Kuopio, Finland.
Neurology. 1991 Apr;41(4):562-5. doi: 10.1212/wnl.41.4.562.
We treated 75 patients with drug-resistant complex partial seizures and secondarily generalized seizures with vigabatrin as additional therapy for 6 months. Twenty-one patients either showed no benefit from vigabatrin treatment or had side effects. The remaining 54 patients entered into the long-term study. The median monthly seizure frequency decreased from 12.5 at baseline to 3.3 at the 3-month visit, and was 3.9 after 5 years of therapy in 28 patients who continued using the drug after the 5-year period. During 5 years of therapy with vigabatrin, 26 patients have withdrawn from the study because of various reasons: loss of efficacy (14), suspected side effects (5), noncompliance (3), administrative reasons (2), pregnancy (1), and epilepsy surgery (1). In all, 19 patients had a greater than 50% seizure frequency reduction at 5 years, representing 35% of the 54 patients who entered the long-term study, or 25% of the 75 patients who were initially recruited into the efficacy study.
我们将75例耐药性复杂部分性发作和继发性全身性发作患者作为额外治疗，使用氨己烯酸治疗6个月。21例患者要么未从氨己烯酸治疗中获益，要么出现了副作用。其余54例患者进入长期研究。中位每月发作频率从基线时的12.5次降至3个月访视时的3.3次，在5年治疗期后，28例继续使用该药物的患者在5年后发作频率为3.9次。在使用氨己烯酸治疗的5年期间，26例患者因各种原因退出研究：疗效丧失（14例）、疑似副作用（5例）、不依从（3例）、管理原因（2例）、妊娠（1例）和癫痫手术（1例）。总体而言，19例患者在5年时发作频率降低超过50%，占进入长期研究的54例患者的35%，或最初纳入疗效研究的75例患者的25%。
